Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SD-101 with Nivolumab and Radiotherapy in Refractory Metastatic Pancreatic Cancer
NCT04050085Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Aug 2019
- Primary completion
- Dec 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nelitolimod in pancreatic adenocarcinoma (PDAC), sponsored by University of California, Davis. Primary endpoint: Incidence of adverse events at 30 days. Started Aug 2019; status: completed.
02
Drugs
nelitolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04050085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050085.